telitacicept
Sponsor VOR · listed as VOR
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
telitacicept is a clinical-stage drug asset sponsored by VOR, listed as VOR. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Dec 31, 2026 (day precision, medium confidence), tied to trial NCT07249632. The asset is in Phase 3 and currently recruiting, studied in Myasthenia Gravis, Ocular. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2026-12-31
As disclosedDec 31, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT07249632
PhasePHASE3
StatusRECRUITING
Lead sponsorRemeGen Co., Ltd.
Listed asVOR
Condition(s)Myasthenia Gravis, Ocular
All tracked catalysts for telitacicept
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-12-31 | READOUT | medium | NCT07249632 |
| 2027-05-31 | READOUT | medium | NCT06456580 |
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More VOR catalysts